Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2NET 1Endocrine 1Breast 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Pleural Effusion 1Insulin-Like Growth Factor I, Resistance To 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × dalotuzumab × Thoracic × Clear all
NCT00951444 2016-07-06

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00799240 2014-11-07

IMPACT

University of Kansas Medical Center

Phase 2 Completed
27 enrolled
Thoracic

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡